These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34070416)

  • 1. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.
    Adachi T; Takeuchi Y; Takaki A; Oyama A; Wada N; Onishi H; Shiraha H; Okada H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.
    Nakanishi H; Kurosaki M; Hosokawa T; Takahashi Y; Itakura J; Suzuki S; Yasui Y; Tamaki N; Nakakuki N; Takada H; Higuchi M; Komiyama Y; Yoshida T; Takaura K; Hayashi T; Kuwabara K; Sasaki S; Izumi N
    J Gastroenterol; 2016 Jun; 51(6):620-7. PubMed ID: 26610908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research progress of arginine vasopressin V2 receptor antagonist tolvaptan in the treatment of cirrhotic ascites].
    Hu YY; Zhang X; Wang YD; Zhao CY
    Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):881-884. PubMed ID: 37394862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.
    Uojima H; Hidaka H; Tanaka Y; Wada N; Kubota K; Nakazawa T; Shibuya A; Sung JH; Kako M; Koizumi W
    Dig Dis; 2020; 38(1):38-45. PubMed ID: 31216537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.
    Arase Y; Kagawa T; Tsuruya K; Sato H; Teramura E; Anzai K; Hirose S; Deguchi R; Shiraishi K; Mine T
    Clin Drug Investig; 2019 Jan; 39(1):45-54. PubMed ID: 30284699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan regulates aquaporin-2 and fecal water in cirrhotic rats with ascites.
    Chen C; Chen RP; Lin HH; Zhang WY; Huang XL; Huang ZM
    World J Gastroenterol; 2016 Mar; 22(12):3363-71. PubMed ID: 27022218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
    Sagawa E; Okubo H; Ando H; Sorin Y; Kanazawa R; Nakadera E; Fukada H; Kokubu S; Miyazaki A
    J Pharmacol Sci; 2019 Apr; 139(4):373-376. PubMed ID: 30857764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of a vascular stricture-related marker is predictive of an early response to tolvaptan, and a low fractional excretion of sodium is predictive of a poor long-term survival after tolvaptan administration for liver cirrhosis.
    Adachi T; Takaki A; Sato S; Tobita H; Kobashi H; Kinomura M; Nakatsuka A; Oyama A; Wada N; Sakata M; Takeuchi Y; Yasunaka T; Onishi H; Shiraha H; Okada H
    Hepatol Res; 2020 Dec; 50(12):1347-1354. PubMed ID: 32939957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
    J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term administration of Tolvaptan to patients with decompensated cirrhosis.
    Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N
    Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
    Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM
    J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites.
    Hirooka M; Koizumi Y; Yano R; Nakamura Y; Sunago K; Yukimoto A; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
    Sci Rep; 2022 May; 12(1):8124. PubMed ID: 35581243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
    Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I; Yamashita S; Kobayashi T; Komatsu M; Sakai T; Komorizono Y; Okada M; Okita K;
    J Int Med Res; 2013 Jun; 41(3):835-47. PubMed ID: 23685892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
    Osawa L; Nakanishi H; Kurosaki M; Kirino S; Inada K; Yamashita K; Hayakawa Y; Sekiguchi S; Wang W; Okada M; Higuchi M; Komiyama Y; Takaura K; Takada H; Kaneko S; Maeyashiki C; Tamaki N; Yasui Y; Tsuchiya K; Itakura J; Takahashi Y; Enomoto N; Izumi N
    Dig Dis; 2022; 40(4):479-488. PubMed ID: 34348262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.